EATG » Hepatitis

Hepatitis

GeoVax and CaroGen to collaborate on development of therapeutic hepatitis B vaccine

Targeting chronic hepatitis B infections affecting more than 240 million people worldwide GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today (February 7) that it is…

Effectiveness of sofosbuvir-containing regimens for hepatitis C, HIV

For patients coinfected with chronic hepatitis C and HIV, treatment regimens containing sofosbuvir are effective but come with a significant risk for adverse effects, according to a meta-analysis published in…

‘Virus-cracking’ molecules advance fight against hepatitis B

BLOOMINGTON, Ind., 6 February 2018 -- Indiana University researchers have made an important step forward in the design of drugs that fight the hepatitis B virus, which can cause liver…

Can England really eliminate hepatitis C by 2025?

The World Health Organisation set a goal to eliminate hepatitis C by 2030. The NHS recently announced that it will go one better than that: it will eliminate the disease…

HCV can reactivate with treatment of non-hepatic cancer

Hepatitis C virus (HCV) reactivation to occur in approximately 1 out of 5 patients treated for non-hepatic cancer, posing renewed risk for hepatic injury and possibly complicating the cancer treatment.…

Multi-disease testing offers new ways to streamline disease management, Unitaid report says

Geneva, 1 February 2018 – Innovators are responding to the world’s growing co-infection crisis by developing devices that can quickly, accurately diagnose multiple diseases at a time. Unitaid’s new landscape…

Deaths from liver cancer nearly double since the 1990s, new figures reveal

London, 1 February 2018: Over the last two decades, deaths caused by liver cancer have increased by 80%, making it one of the fastest-growing causes of cancer deaths worldwide. According…

Harm reduction scale-up needed to eliminate HCV in people who inject drugs, European model predicts

Elimination of hepatitis C among people who inject drugs in Europe will require simultaneous scale-up of direct-acting antiviral treatment, needle and syringe programmes (NSP) and opioid substitution treatment (OST), and…

Patients with HCV, chronic kidney disease less likely to receive antivirals

Patients with hepatitis C (HCV) and advanced chronic kidney disease (CKD) are less likely to receive treatment for their viral infection than patients with less-advanced CKD and HCV, according to…

Georgia: 98% of people in hepatitis C elimination program cured

Around 45,000 people have gone through medical treatment for hepatitis C in Georgia, 98 percent of whom were cured, the head of Georgia’s National Center for Disease Control and Public…